TEL AVIV, ISRAEL- December 12, 2006 – Compugen Ltd. (NASDAQ: CGEN) announced today that Eli Zangvil, MD, Vice President Business Development, will participate in a panel discussion at the RBC Capital Markets Healthcare Conference, at the Westin New York at Times Square in New York City. The “Diagnostics: From Discovery to Point-Of-Care” panel discussion will begin at 2:00 p.m. EST on Thursday, December 14, 2006.
A live webcast of the panel discussion will be available on Compugen’s Website and at http://www.wsw.com/webcast/rbc62/panel32, and a replay will be available for 30 days following the presentation.
Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company’s powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company’s decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen’s product discovery efforts and its initial discovery engines have focused mainly within the areas of cancer, immune-related and cardiovascular diseases. The Company’s primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies. Compugen has established an agricultural biotechnology affiliate – Evogene, and a small-molecule drug discovery affiliate – Keddem Bioscience. For additional information, please visit Compugen’s corporate Website at www.cgen.com.